Prevalence of metabolic syndrome in female and male patients at risk of psychosis
Prevalence of metabolic syndrome in female and male patients at risk of psychosis
复制标题
DOI：
10.1016/j.schres.2016.09.012
复制
发表时间：
2017-03-01
影响因子：
4.5
通讯作者：
Moebus, Susanne
中科院分区：
文献类型：
--
作者：
Cordes, Joachim;Bechdolf, Andreas;Moebus, Susanne
代谢综合征（MetS）是精神分裂症患者高死亡率的最常见因素之一。最近关于这个主题的研究表明，许多被研究的患者实际上处于服药状态。因此，尚不清楚 MetS 是否与疾病本身或用于治疗该疾病的药物存在因果关系。在这项研究中，对临床上具有首发精神病 (CHR) 高风险的患者进行了 MetS 患病率的检查。将 N = 144 名未接受药物治疗且未使用过抗精神病药物的 CHR 患者（年龄在 18 岁至 42 岁之间且患有未表现的前驱症状）与来自“德国代谢和心血管风险研究”(GEMCAS) 的 N = 3995 名个体进行比较。与 GEMCAS 样本相比，CHR 组中个体 MetS 标准的流行率略高；具体而言，CHR 患者的血压升高（35.0% vs. 28.0%）、腰围增加（17.6% vs. 15.1%）以及空腹血糖升高（9.4% vs. 4.0%）。此外，对照组 HDL 胆固醇浓度降低率较低（20.2% vs. 13.3%）。 (C) 2016 Elsevier B.V. 保留所有权利。
Metabolic Syndrome (MetS) is one of the most common factors underlying the high rate of mortality observed in patients with schizophrenia. Recent research on this topic revealed that many of the patients studied were, in fact, in a medicated state. As such, it is unclear whether MetS is causally associated with the disorder itself or the medication used to treat it. In this study, patients with a clinically high risk of expressing first episode psychosis (CHR) were examined regarding the prevalence of MetS. N = 144 unmedicated and antipsychotic-naive CHR patients, aged between 18 and 42 years and suffering from unmanifested prodromal symptoms, were compared with a cohort of N = 3995 individuals from the "German Metabolic and Cardiovascular Risk Study" (GEMCAS). A slightly higher prevalence of individual MetS criteria was observed in the CHR group compared to the GEMCAS sample; specifically, the following were noted: a higher blood pressure (35.0% vs. 28.0%), increased waist circumference (17.6% vs. 15.1%), and increased fasting blood glucose (9.4% vs. 4.0%) in CHR patients. Additionally, the rate of reduced HDL cholesterol concentrations was lower in the control group (20.2% vs. 13.3%). (C) 2016 Elsevier B.V. All rights reserved.